Share the Science: Dr. Mitchell Horwitz - Improved Clinical Outcomes in Cord Blood Transplantation

Save the Cord Foundation and WellSky are proud to welcome Dr. Mitchell Horwitz, as our featured speaker for our next edition of Share the Science on Wednesday, June 22nd, 2022 1pm ET. Join us to hear Dr. Horwitz discuss the results from his recent research comparing Omidubicel to Standard Myeloablative Umbilical Cord Blood Transplantation.  RECORDING NOW AVAILABLE
​
Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field.  As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here.

Looking to the future of cord blood transplantation

For over 30 years, cord blood stem cell transplants have been saving lives and bringing new hope to patients fighting over 80 different life-threatening diseases including leukemia, lymphoma and thalassemia. However, despite this impressive track record, transplant doctors are not complacent, but constantly looking for ways to improve on the transplant process whether using cord blood, bone marrow or both.

​In this spirit, Dr. Mitchell Horwitz and his team at Duke University Medical Center have led the way in new and pioneering cord blood research. Recently, the team published their encouraging results from a phase 3 randomized study on the efficacy of omidubicel vs. standards myeloablative umbilical cord blood transplantation. Omidubicel is an ex vivo expanded hematopoietic progenitor cell and non-expanded myeloid and lymphoid cell product that is derived from a single umbilical cord blood unit.

As part of Dr. Horwitz' study, between January 2017 and January 2020, 125 patients ages 13 to 65 years with hematologic malignancies were randomly assigned to this study. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease. 

Join us to learn about the details of this phase 3 study and explore ways that doctors can improve cord blood transplants through innovation.

SHARE THE SCIENCE
with

Mitchell Horwitz, MD
Adult Blood and Marrow Transplant Program and Professor of Medicine at the Duke University Medical Center
 
"Improved Clinical Outcomes with Omidubicel vs. Standard Myeloablative Umbilical Cord Blood Transplantation"

Free webinar.  Open to the public.
​
Wednesday, June 22nd, 2022  1pm ET

RECORDING NOW AVAILABLE in the Share the Science Archive

Register Now for Share the Science with Dr. Mitchell Horwitz

About the speaker

Mitchell Horwitz, M.D.

​Adult Blood and Marrow Transplant Program and Professor of Medicine at the Duke University Medical Center

​With over 20 years of experience, Dr. Horwitz specializes in allogeneic stem cell transplantation using umbilical cord blood grafts; allogenic stem cell transplantation for Sickle Cell Disease; prevention of acute graft versus host disease through donor stem cell graft manipulation; and improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation or third party thymus transplantation.

---

We wish to thank Dr. Mitchell Horwitz for volunteering his time to speak on
Share the Science and sharing his valuable insight
on the ways to improve cord blood transplantation.
​​
We also wish to also thank our generous sponsor and partner for this event,
WellSky Health, who continue to support cord blood
education through our “Share the Science” series.